Pub Date : 2022-01-05DOI: 10.4274/mjima.galenos.2021.2021.2
A. Mirahmadizadeh, B. Yeganeh, J. Hassanzadeh, L. Badiee, M. Vali, Z. Maleki, A. Akbari, Tahereh Pakdel, H. Ghaem
{"title":"Value of Rapid antigen test in comparison with RT-PCR method for diagnosis of COVID-19","authors":"A. Mirahmadizadeh, B. Yeganeh, J. Hassanzadeh, L. Badiee, M. Vali, Z. Maleki, A. Akbari, Tahereh Pakdel, H. Ghaem","doi":"10.4274/mjima.galenos.2021.2021.2","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2021.2021.2","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"10 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88468615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-05DOI: 10.4274/mjima.galenos.2021.2021.1
Soibam Ngasotter, S. Mukherjee, S. K. Singh, Deeksha Bharti, Ramjanul Haque, Shubham Varshney, Chinmay Nanda, David Waikhom, M. S. Devi, Asem Sanjit Singh
{"title":"Prevalence, Virulence and Antibiotic Resistance Profiles of Vibrio parahaemolyticus from Seafood and its Environment: An Updated Review","authors":"Soibam Ngasotter, S. Mukherjee, S. K. Singh, Deeksha Bharti, Ramjanul Haque, Shubham Varshney, Chinmay Nanda, David Waikhom, M. S. Devi, Asem Sanjit Singh","doi":"10.4274/mjima.galenos.2021.2021.1","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2021.2021.1","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74831949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-05DOI: 10.4274/mjima.galenos.2021.2021.3
A. Laktib, K. Nayme, A. Hamdaoui, M. Timinouni, M. Hassi, A. Aitalla, F. Msanda, Mohammed Bourouache, Mohamed El Yaagoubi, Rachida Mimoun, B. Bihadassen, F. Hamadi
{"title":"Antibacterial activity of Lavandula mairei Humbert essential oil against carbapenem- resistant Acinetobacter baumannii","authors":"A. Laktib, K. Nayme, A. Hamdaoui, M. Timinouni, M. Hassi, A. Aitalla, F. Msanda, Mohammed Bourouache, Mohamed El Yaagoubi, Rachida Mimoun, B. Bihadassen, F. Hamadi","doi":"10.4274/mjima.galenos.2021.2021.3","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2021.2021.3","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"56 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73809322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.4274/mjima.galenos.2022.2021.15
A. Yilmaz, S. Ateş, A. Kosif
{"title":"Chlorhexidine Gluconate Usage in Perıoperative Skin Cleansing in Reducing Surgical Site Infection and Bacterial Colonization: A Randomized Controlled Trial","authors":"A. Yilmaz, S. Ateş, A. Kosif","doi":"10.4274/mjima.galenos.2022.2021.15","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2021.15","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"263 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75109039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.4274/mjima.galenos.2022.2021.14
Bahise Çağla Taşkın Dalgıç, G. Yenişehirli, B. Otlu, E. Tanrıverdi, A. Yenişehirli, Y. Bulut
{"title":"In vitro Evaluation of the Relationship Between Biofilm Production and Antimicrobial Resistance in Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus Isolates","authors":"Bahise Çağla Taşkın Dalgıç, G. Yenişehirli, B. Otlu, E. Tanrıverdi, A. Yenişehirli, Y. Bulut","doi":"10.4274/mjima.galenos.2022.2021.14","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2022.2021.14","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"65 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83159643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-13DOI: 10.4274/mjima.galenos.2021.2021.68
Sibel Bölükcü, D. Karakuş, G. Okay, Y. Akkoyunlu, Bilge Sümbül, B. Durdu, M. M. Koç, T. Aslan
Introduction: Interleukin-6 (IL-6) is the key cytokine in "cytokine release syndrome" and associated with the lung fibrosis. Tocilizumab (TCZ) reduces the negative effects of inflammation by blocking the binding of IL-6 to its receptor. Materials and Methods: This was a retrospective observational cohort study. Patients with microbiologically-confirmed Severe acute respiratory syndrome-Coronavirus-2 infection who received TCZ and standard treatment for Coronavirus disease-2019 (COVID-19) were evaluated in the study. Results: A total of 64 severe and moderate COVID-19 cases were included in this study. The mean age of the patients was 57.8 +/- 13.9 years and 68.8% (n=44) of them were male, 54.7% (n=35) of them had a severe COVID-19 infection and 45.3% (n=29) of them received TCZ therapy. Standard treatment group and TCZ group were compared in terms of the mortality and clinical changes such as a fever response and need for oxygen support. Fever response was detected within the first day of the treatment in the TCZ group. Additionally, need for oxygen support was lower in the TCZ group, although the difference was not statistically significant. Admission to the intensive care unit and mortality were lower in the TCZ group. Conclusion: Efficacy of TCZ should be assessed in randomized placebo-controlled trials in the early phase of COVID-19 patients.
{"title":"Efficacy of Tocilizumab in Patients with Moderate and Severe COVID-19: A Retrospective Cohort Study of Single Center","authors":"Sibel Bölükcü, D. Karakuş, G. Okay, Y. Akkoyunlu, Bilge Sümbül, B. Durdu, M. M. Koç, T. Aslan","doi":"10.4274/mjima.galenos.2021.2021.68","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2021.2021.68","url":null,"abstract":"Introduction: Interleukin-6 (IL-6) is the key cytokine in \"cytokine release syndrome\" and associated with the lung fibrosis. Tocilizumab (TCZ) reduces the negative effects of inflammation by blocking the binding of IL-6 to its receptor. Materials and Methods: This was a retrospective observational cohort study. Patients with microbiologically-confirmed Severe acute respiratory syndrome-Coronavirus-2 infection who received TCZ and standard treatment for Coronavirus disease-2019 (COVID-19) were evaluated in the study. Results: A total of 64 severe and moderate COVID-19 cases were included in this study. The mean age of the patients was 57.8 +/- 13.9 years and 68.8% (n=44) of them were male, 54.7% (n=35) of them had a severe COVID-19 infection and 45.3% (n=29) of them received TCZ therapy. Standard treatment group and TCZ group were compared in terms of the mortality and clinical changes such as a fever response and need for oxygen support. Fever response was detected within the first day of the treatment in the TCZ group. Additionally, need for oxygen support was lower in the TCZ group, although the difference was not statistically significant. Admission to the intensive care unit and mortality were lower in the TCZ group. Conclusion: Efficacy of TCZ should be assessed in randomized placebo-controlled trials in the early phase of COVID-19 patients.","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90657800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-13DOI: 10.4274/mjima.galenos.2021.2021.67
S. Boni, G. Marín, Laura Campaña, Lupe Marin, Gina Marin, Soledad Risso Patron, Fernanda Gabriel, A. Corso, Valeria Garay, M. Limeres
{"title":"Correlation of “Watch” Antibiotic Consumption with Gram-negative Bacteria Resistance. Analysis at a Country Level","authors":"S. Boni, G. Marín, Laura Campaña, Lupe Marin, Gina Marin, Soledad Risso Patron, Fernanda Gabriel, A. Corso, Valeria Garay, M. Limeres","doi":"10.4274/mjima.galenos.2021.2021.67","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2021.2021.67","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"59 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77770824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-13DOI: 10.4274/mjima.galenos.2021.2020.66
A. Farahani, Armaghan Vaez Lari, H. Forouzandeh, Jebreil Shamseddin, Hossein Hafezi, I. Ahmadi, Kusar Zarebi, Parisa Mohseni, Z. Forouzandeh, Fatemeh Fariyabi
{"title":"Evaluation of Bacterial Profile and Drug Resistance Patterns of Blood Culture Isolates in Amir Al-Momenin Hospital of Gerash, Iran","authors":"A. Farahani, Armaghan Vaez Lari, H. Forouzandeh, Jebreil Shamseddin, Hossein Hafezi, I. Ahmadi, Kusar Zarebi, Parisa Mohseni, Z. Forouzandeh, Fatemeh Fariyabi","doi":"10.4274/mjima.galenos.2021.2020.66","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2021.2020.66","url":null,"abstract":"","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"8 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88584318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-13DOI: 10.4274/mjima.galenos.2021.2021.65
A. Topçu, Nurdan Papila-Topal, A. Batırel
Introduction: Patients with COVID-19 are at increased risk of thromboembolic events during hospitalization and after discharge. Current guidelines recommend use of extended thromboprophylaxis in hospitalized COVID-19 patients who have high risk of post-discharge venous thromboembolism and low risk of bleeding. We aimed to report our experience regarding different low-molecular-weight heparins administered post-discharge in a COVID-19 patient population with high-thromboembolic and low-bleeding risk. Methods: This was a single-center, retrospective, observational study. Consecutive patients admitted with a confirmed diagnosis of COVID-19 between March 16 and July 16, 2020, were assessed for enrollment. Patients were included if they received prophylaxis with low-molecular weight heparins after discharge, were 18 years of age, patients with intensive care unit admission, and patients who experienced venous and/or arterial thromboembolism prior to discharge were excluded. Extended thromboprophylaxis with either enoxaparin 4000 IU once daily or bemiparin 3500 IU once daily was prescribed if a patient had a modified IMPROVE VTE score of >= 4, or a modified IMPROVE score of >= 2 and a D-dimer level of >= 2 times the reference range. Patients were followed-up for 30 days after discharge. Primary endpoint was occurrence of radiologically confirmed symptomatic venous thromboembolism (deep vein thrombosis and/ or pulmonary embolism). Results: A total of 3498 consecutive patients were hospitalized with a diagnosis of COVID-19. Of them, 38 (20 women) received extended thromboprophylaxis. Mean of age was 66.6 +/- 15.7 years. Twenty-five patients received enoxaparin, and 13 received bemiparin. Three patients in the enoxaparin group and none of the patients in the bemiparin group experienced post-discharge venous thromboembolism (p=0.681). Major bleeding occurred in one patient in the enoxaparin group, and in zero patients in the bemiparin group (p=0.456). Conclusion: Enoxaparin and bemiparin have similar prophylactic properties when used for prevention of post-discharge venous thromboembolism in COVID-19 survivors who have high thromboembolic and low bleeding risk.
{"title":"Bemiparin Versus Enoxaparin for Extended Thromboprophylaxis in COVID-19 Patients at High Risk of Venous Thromboembolism","authors":"A. Topçu, Nurdan Papila-Topal, A. Batırel","doi":"10.4274/mjima.galenos.2021.2021.65","DOIUrl":"https://doi.org/10.4274/mjima.galenos.2021.2021.65","url":null,"abstract":"Introduction: Patients with COVID-19 are at increased risk of thromboembolic events during hospitalization and after discharge. Current guidelines recommend use of extended thromboprophylaxis in hospitalized COVID-19 patients who have high risk of post-discharge venous thromboembolism and low risk of bleeding. We aimed to report our experience regarding different low-molecular-weight heparins administered post-discharge in a COVID-19 patient population with high-thromboembolic and low-bleeding risk. Methods: This was a single-center, retrospective, observational study. Consecutive patients admitted with a confirmed diagnosis of COVID-19 between March 16 and July 16, 2020, were assessed for enrollment. Patients were included if they received prophylaxis with low-molecular weight heparins after discharge, were 18 years of age, patients with intensive care unit admission, and patients who experienced venous and/or arterial thromboembolism prior to discharge were excluded. Extended thromboprophylaxis with either enoxaparin 4000 IU once daily or bemiparin 3500 IU once daily was prescribed if a patient had a modified IMPROVE VTE score of >= 4, or a modified IMPROVE score of >= 2 and a D-dimer level of >= 2 times the reference range. Patients were followed-up for 30 days after discharge. Primary endpoint was occurrence of radiologically confirmed symptomatic venous thromboembolism (deep vein thrombosis and/ or pulmonary embolism). Results: A total of 3498 consecutive patients were hospitalized with a diagnosis of COVID-19. Of them, 38 (20 women) received extended thromboprophylaxis. Mean of age was 66.6 +/- 15.7 years. Twenty-five patients received enoxaparin, and 13 received bemiparin. Three patients in the enoxaparin group and none of the patients in the bemiparin group experienced post-discharge venous thromboembolism (p=0.681). Major bleeding occurred in one patient in the enoxaparin group, and in zero patients in the bemiparin group (p=0.456). Conclusion: Enoxaparin and bemiparin have similar prophylactic properties when used for prevention of post-discharge venous thromboembolism in COVID-19 survivors who have high thromboembolic and low bleeding risk.","PeriodicalId":53879,"journal":{"name":"Mediterranean Journal of Infection Microbes and Antimicrobials","volume":"9 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79165845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：